The Zhitong Finance App learned that according to reports, SanegeneBio (SaneGeneBio) submitted a listing application to the Hong Kong Stock Exchange by means of confidential submission, with the goal of raising hundreds of millions of dollars in an IPO next year. The company has already hired Morgan Stanley and CICC as co-sponsors.

Established in 2021, Shengyin Biotech is committed to developing RNA interference (RNAi) therapies for autoimmune diseases, cardiovascular diseases, obesity, and metabolic diseases. According to Shengyin Biotech, RNAi technology can reverse silence pathogenic genes. The company has R&D centers in Boston, Shanghai and Suzhou in the United States, and has so far initiated clinical trials of 4 experimental drugs.

Shengyin Biotech completed Series B financing of US$110 million in December 2025, including an international sovereign fund, China Biopharmaceuticals (01177), and Qingchi Capital, and received strategic investment from Eli Lilly. In addition, current shareholder Gao Lin Venture Capital also has continued support. The company completed a strategic cooperation with Eli Lilly in November 2025 for RNAi drug development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.